Synapse

← JHEP Reports

Papers in JHEP Reports

Page 6 · newest first

  1. Liver biopsy quality criteria to exclude cirrhosis in case of suspicion of porto-sinusoidal vascular disorderJHEP Reports · 2025
  2. Single-cell analysis of heterogeneity in reverted hiPSC-derived human hepatic stellate cellsJHEP Reports · 2025
  3. Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in EuropeJHEP Reports · 2025
  4. STAT1 drives the immune landscape of murine Toll-like receptor 9-induced liver inflammationJHEP Reports · 2025
  5. Impact of LEAP-012 and EMERALD-1 in the management of HCCJHEP Reports · 2025
  6. Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)JHEP Reports · 2025
  7. Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysisJHEP Reports · 2025
  8. Clinical practice and implications of biomarker testing in biliary tract cancer: An observational studyJHEP Reports · 2025
  9. Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescenceJHEP Reports · 2025
  10. Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib – A phase II trial (PEMRAD)JHEP Reports · 2025
  11. FGF1 ameliorates hepatic steatosis through acute activation of the unfolded protein response and VLDL productionJHEP Reports · 2025
  12. PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosisJHEP Reports · 2025
  13. Rising burden of steatotic liver disease in women of childbearing age and projections to 2035JHEP Reports · 2025
  14. The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC trialJHEP Reports · 2025
  15. Validation of a data-driven clustering model for MASLD: Evidence from three large-scale Asian cohortsJHEP Reports · 2025
  16. Effects of hypothermic oxygenated machine perfusion on bile composition after liver transplantation – Findings from a randomized controlled trialJHEP Reports · 2025
  17. Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseJHEP Reports · 2025
  18. Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DJHEP Reports · 2025
  19. Pathological response ≥90% predicts survival in HCC treated with neoadjuvant loco-regional therapies: A retrospective cohort studyJHEP Reports · 2025
  20. Hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD)JHEP Reports · 2025
  21. Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinomaJHEP Reports · 2025
  22. Fine needle aspirates characterise the hepatocellular carcinoma immune niche to predict immune checkpoint inhibitor outcomesJHEP Reports · 2025
  23. Navigating second-line therapy after immunotherapy in advanced HCC☆JHEP Reports · 2025
  24. Orphan drug uttroside B impedes MASH progression and HCC development in experimental modelsJHEP Reports · 2025
  25. Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in miceJHEP Reports · 2025
  26. Lactococcus A phages predict ACLF while Enterococcus B phages predict bacterial infection in decompensated cirrhosisJHEP Reports · 2025
  27. Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulationJHEP Reports · 2025
  28. Transcriptome of monocytes from liver, brain and bone marrow reveals organ-specific features in aging and alcohol misuseJHEP Reports · 2025
  29. Binge drinking acutely induces hepatic steatosis which is readily reversible: A real-world observational study in healthy adultsJHEP Reports · 2025
  30. Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASHJHEP Reports · 2025
  31. Viral sequence analysis of chronic hepatitis B patients treated with the siRNA JNJ-73763989 in phase II clinical trialsJHEP Reports · 2025
  32. Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysisJHEP Reports · 2025
  33. Challenges in the diagnosis and treatment of genetic cholestasis in adultsJHEP Reports · 2025
  34. From model to man: Understanding Tregs' dual role in MASLDJHEP Reports · 2025
  35. Higher prevalence of cytomegalovirus and Epstein–Barr virus in acute-on-chronic liver failureJHEP Reports · 2025
  36. HBV X protein regulates cancer stemness and tumor invasiveness through SENP1 in hepatocellular carcinomaJHEP Reports · 2025
  37. Enhanced nuclear localization of small heterodimer partner in metabolic dysfunction-associated steatohepatitisJHEP Reports · 2025
  38. 3D endothelial cell scaffolds protect liver explants and exhibit therapeutic effects on liver fibrosisJHEP Reports · 2025
  39. Failure-to-rescue as a determinant of overall survival following resection for perihilar cholangiocarcinomaJHEP Reports · 2025
  40. Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)JHEP Reports · 2025
  41. Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitisJHEP Reports · 2025
  42. The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytesJHEP Reports · 2025
  43. High systemic inflammation response index and increased cardiovascular risk and mortality in MASLD: A prospective cohort studyJHEP Reports · 2025
  44. Macrophage MRC2 deficiency mitigates HFD-induced MASLD by downregulating CD147-regulated TNF-α productionJHEP Reports · 2025
  45. Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyJHEP Reports · 2025
  46. Stage-dependent effects of systemic ASBT inhibition in a cholestasis-induced cholemic nephropathy mouse modelJHEP Reports · 2025
  47. Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluationJHEP Reports · 2025
  48. Disparities in transplant access and outcomes after first cirrhosis decompensation in alcohol-related liver diseaseJHEP Reports · 2025
  49. PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort studyJHEP Reports · 2025
  50. FKBP9 enhances IGF2BP1-mediated m6A recognition to promote hepatocellular carcinoma progressionJHEP Reports · 2025